News|Videos|September 9, 2025

Are There Benefits to Combination Therapy for Drug-Resistant Pseudomonas Infections?

Pranita Tamma, MD, MHS, continues her conversation about a study she was involved in that compared ceftolozane-tazobactam and ceftazidime-avibactam. She discusses how an analysis of infection source and treatment patterns found no evidence that combination therapy improves outcomes in patients with drug-resistant Pseudomonas, consistent with prior studies and clinical trials.

In this short series, Pranita Tamma, MD, MHS, associate professor of pediatrics in the Division of Pediatric Infectious Diseases at The Johns Hopkins University School of Medicine, has a discussion about ceftolozane-tazobactam vs ceftazidime-avibactam for gram-negative resistant Pseudomonas aeruginosa infections and the latest data supporting these decisions.

In one retrospective observational study, which compared ceftolozane-tazobactam and ceftazidime-avibactam and was funded by the National Institutes of Health, the findings showed similar 30-day mortality rates but higher resistance emergence in the ceftolozane-tazobactam group (38% vs 25%). Tamma was the senior investigator in this trial.

Below is a response from a question about infection source and combination therapy.

Contagion: Were there any notable differences in patient outcomes based on infection source or use of combination therapy in either group?

Pranita Tamma, MD, MHS: We also examined other variables that might differ between the groups, including the source of infection and the use of combination therapy. As expected, since these patients were infected with Pseudomonas, the vast majority had pneumonia, followed by bacteremia. We did not find any notable differences between the groups—either at baseline or in exploratory analyses of mortality by infection source.

Similarly, only a minority of patients received combination therapy, which we defined as adding a second agent such as an aminoglycoside, fluoroquinolone, or polymyxin. Fewer than 15% of the cohort received such therapy. In general, there are limited effective options for combination therapy: the only aminoglycoside with breakpoints for Pseudomonas in pneumonia and bloodstream infections is tobramycin; polymyxins are never reported as “susceptible” due to concerns about efficacy; and by definition, DTR Pseudomonas are resistant to fluoroquinolones. This leaves very few opportunities for a viable second agent.

We did not observe any trend suggesting better outcomes with combination therapy. This aligns with prior observational studies in drug-resistant Pseudomonas as well as clinical trials in pan-susceptible Pseudomonas, all of which have failed to show a benefit from adding a second agent. So, not surprisingly, we did not see an advantage with combination therapy. Unfortunately, it would have been encouraging if we had found such a benefit, but we did not.


The conversation was edited for grammar and clarity.


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Measles Update: November 13, 2026
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.